生物制药

先声真有意思，上次花7位数的价格买了依达拉奉，这次又花九位数的价格买恩度Tongue

=============================================================================================================

相关疾病：
值得一读。
Why such success? Is it a pure coincidence? Or has China something to offer that other
countries don’t have?
（在USA，EU都失败的东西）为什么在中国成功呢？纯属巧合吗？还是中国提供了其他国家不曾提供的便利呢？One reason why experimental therapies have reached the market in China, but languished in the West, is cultural.in the United States, treatments, such as gene therapy, have been stigmatized by highly publicized failures like the death of Jesse Gelsinger during a trial at the University of Pennsylvania; this stigma does not exist in China.
原因一：文化。Jesse Gelsinger Case对于美国人接受生物疗法心理上存在阴影。
Jesse Gelsinger Case：一个基因治疗失败的案例，Jesse Gelsinger，18岁，男性，患有轻度鸟氨酸转移酶缺乏症（OTC），该症是由于代谢紊乱影响到氨的降解，但利用药物治疗和低蛋白饮食可使疾病得到控制。1999年9月，Gelsinger自愿参加针对OTC缺乏症的基因治疗的I期临床试验。结果对病毒载体产生严重免疫反应，后死于多器官功能衰竭。美国宾州大学人类基因治疗研究所进行的这项临床试验，是研究对患有致命的OTC缺乏症的婴儿的基因治疗方法。而这一I期临床试验对Gelsinger并没有预期的利益。
Another possible key factor for success is the ability of Chinese firms to easily recruit
patients.
原因二：中国容易招募到病人。
“All three cases are a result of the heavy, even desperate, government investments,” Medgenn receives most of the RMB100 ($12.4) million research funding from various levels of government in the coastal province Shandong, one of the richest in China. Similarly, （深圳）Sibiono receives nearly all of its RMB80 ($9.6) million research funding from government bodies, public foundations and major universities.
（不知道是不是）原因三：政府从纳税人手里凑了一大笔钱，总不能打水漂吧？（是原文的最后一段，我觉得是原因三）
Are the successes of these Chinese companies likely to make the country more attractive to US firms？
既然中国的生物药物公司取得这么多成功（2003年3月深圳的Sibiono，2005年9月烟台的Medgenn Co.，2005年11月上海的Sunway都有新药上市），是否会吸引美国的公司到中国来呢？
US companies, however, would still not necessarily opt for the Chinese approval system. For example, Introgen intends to sell its gene therapy products throughout the world, but the company has no intention of moving its testing to China or anywhere else to speed development. “We’re very focused on creating the global standard for this new class of products, and that’s going to be defined in the US and in Europe”
结论是：（尽管中国对生物药容易上市）旦人家不会选择在中国上市的。人家关注的是符合US，EU框价下的新药上市标准（全球标准）。
补充一点：
Intellectual property (IP) could be a factor limiting export of the technology to the US
market
另外谈到今后出口，可能引起知识产权的纠纷

强烈建议大家读一读nature Group旗下的nature biotechnology杂志,
volume 24,number 2,february 2006,篇名"china offers alternative gateway for experimental drugs".看了之后一定让你明白所谓国家一类抗癌新药恩度的真相.

==============================================================================================================

文章比较中立客观，里面似乎也没有什么“真相”，都是事实，大家也都知道（恩度的来历，中国的现状，美国的评论，Folkman本人的意见……），虽然结尾略带点儿西方媒体一贯的酸味（尤其是那张配图）。相反，国内的一些媒体的报道反而让人反胃。
希望“恩度”真的把恩惠普渡众多肿瘤患者。